Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bergapten (5-methoxypsoralen) is a naturally occurring furanocoumarin found in citrus peels, parsley, and angelica root that functions as a photosensitizing agent. Its primary mechanism involves intercalating into DNA strands upon UVA activation, forming cyclobutane adducts that modulate cellular proliferation and immune responses in skin tissue.
Origin & History
Bergapten (5-methoxypsoralen) is a naturally occurring furanocoumarin found in essential oils from bergamot (Citrus bergamia) and other citrus species. It is typically extracted from bergamot oil or citrus fruits via solvent extraction or steam distillation of plant materials.
Research Narrative (Provisional)
Clinical trials have primarily evaluated bergapten in photochemotherapy for skin disorders, with one randomized trial (n=169) comparing oral bergapten at 0.6-1.2 mg/kg to 8-MOP showing similar efficacy with minimal side effects. A trial in 40 atopic dermatitis patients demonstrated bergapten's superiority over UVA1 alone with 12-month follow-up benefits (PMID: 3279089 for related psoriasis photochemotherapy summary).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Bergapten (5-methoxypsoralen) is a naturally occurring furocoumarin compound, not a nutritional ingredient, and thus lacks conventional macronutrient or micronutrient content. It is a pure bioactive phytochemical with molecular formula C12H8O4 and molecular weight of 216.19 g/mol. Found naturally in plants at varying concentrations: bergamot oil contains approximately 0.3–1.8% bergapten by weight, celery (Apium graveolens) contains roughly 0.004–0.085 mg/g fresh weight, parsley contains approximately 0.003–0.02 mg/g, and fig leaves contain up to 0.12 mg/g. Grapefruit juice contains trace amounts (~0.001–0.01 mg/mL). As a furocoumarin, it contains no protein, fat, carbohydrates, fiber, vitamins, or minerals. Its biological activity is not nutritional but pharmacological, acting as a photosensitizing agent that intercalates with DNA upon UVA activation (320–400 nm). Bioavailability when ingested orally is moderate, with peak plasma concentrations reached within 1–2 hours; it undergoes hepatic first-pass metabolism via CYP450 enzymes (notably CYP3A4 inhibition). Lipophilic in nature (logP approximately 1.9), facilitating membrane permeability. Used therapeutically at doses of approximately 20–40 mg per session in photochemotherapy (PUVA) protocols, considerably lower than 8-methoxypsoralen.
Reported Mechanism (Provisional)
Bergapten absorbs UVA radiation (320–400 nm) and undergoes a photochemical reaction to form mono- and bi-functional covalent crosslinks with pyrimidine bases in DNA, inhibiting replication in hyperproliferating keratinocytes central to psoriasis pathology. It also modulates the expression of cytokines including IL-2 and TNF-α and suppresses T-lymphocyte activity by inhibiting calmodulin-dependent processes. Additionally, bergapten interacts with melanocyte-stimulating pathways, upregulating tyrosinase activity and promoting melanin synthesis relevant to vitiligo repigmentation.
Clinical Narrative (Provisional)
Randomized controlled trials comparing bergapten-PUVA (photochemotherapy) to 8-methoxypsoralen (8-MOP)-PUVA in psoriasis patients have demonstrated equivalent clearance rates—typically 70–85% improvement in PASI scores—while bergapten produced significantly lower rates of nausea and hepatotoxicity. A double-blind crossover study in approximately 50 psoriasis patients found that 5-MOP required modestly higher UVA doses for equivalent response but caused gastrointestinal side effects in fewer than 10% of subjects versus roughly 40% with 8-MOP. Evidence for vitiligo is moderate, with open-label and small controlled studies showing partial to complete repigmentation in 40–60% of patients after 6–12 months of topical or oral 5-MOP-PUVA therapy. Preliminary in vitro and animal data suggest antifungal properties against dermatophytes, though human clinical trials in this application remain limited.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.